NEW YORK, June 17, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, today announced the geographic expansion of intellectual property protection around its lead product candidate, AMR-001, with the notice of a patent allowance in Canada. This patent is in the family titled "Compositions and Methods of Vascular Injury Repair" and protects a chemotactic stem cell product enriched for CD34+ cells that treats injury from acute myocardial infarction ("AMI").
"This incremental patent will bring AMR-001's total worldwide patent coverage to ten patents," said Dr. Andrew L. Pecora, Chief Medical Officer of NeoStem. "If our trial results warrant regulatory approval, after launch in the U.S., Canadian expansion of AMR-001 sales would be a logical step and creates the potential to access a nearby market where heart attack and cardiovascular disease are significant threats to public health."
According to reports, cardiovascular disease is a significant problem in Canada. The population of Canada is approximately 35.5 million with an estimated 70,000 heart attacks occurring each year. Heart disease accounts for over 20% of deaths in Canada.NeoStem's AMR-001 is a cell therapy in development for the treatment of cardiovascular disease. The Company is on track to complete enrollment this year in the Phase 2 PreSERVE AMR-001 double-blinded clinical trial to investigate AMR-001's safety and efficacy in preserving heart function after a heart attack in a particular type of post-AMI patient. NeoStem expects to have the first data readout available six to eight months after the last patient is enrolled. If approved by the U.S. Food and Drug Administration ("FDA") and/or other worldwide regulatory agencies, AMR-001 would address a significant unmet medical need in the treatment of AMI and position the Company to capture a meaningful share of the worldwide AMI market.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV